OUR PIPELINE


We are building a pipeline of *in vivo* and *ex vivo* therapies, as well as continuing to develop innovative modular platform capabilities.



LAST UPDATED: OCTOBER 7, 2024

IN VIVO PROGRAMS

IN VIVO CRISPR **is** the therapy **GENETIC DISEASES**



EX VIVO PROGRAMS

EX VIVO CRISPR **creates** the therapy IMMUNO-ONCOLOGY / AUTOIMMUNE DISEASE

PROGRAM	APPROACH	RESEARCH AND PRECLINICAL	EARLY-STAGE CLINICAL	LATE-STAGE CLINICAL	PARTNERS	
Research Programs	Allogeneic and other					
AATD: Alpha-1 Antitrypsin Deficiency Lead refers to lead development and commercial party.			** NTLA-2001 is no *** Hemophilia A pro	 * Intellia is advancing both wholly-owned and partnered programs. ** NTLA-2001 is now known as nexiguran ziclumeran (nex-z) *** Hemophilia A program is in the research stage. Hemophilia B is being advanced by Regeneron. Intellia is eligible for milestones and royalties. 		